{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:48:07Z","timestamp":1793641687087,"version":"4.5.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Macular Disease Foundation Australia (MDFA). There is no grant reference number."},{"DOI":"10.13039\/100009399","name":"Macular Disease Foundation Australia","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1038\/s41433-023-02407-0","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T08:02:44Z","timestamp":1674633764000},"page":"2736-2743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Risk factors for poorer quality of life in patients with neovascular age-related macular degeneration: a longitudinal clinic-based study"],"prefix":"10.1038","volume":"37","author":[{"given":"Kim Van","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshil Dharamdasani","family":"Detaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Burlutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8332-1082","authenticated-orcid":false,"given":"Bamini","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"2407_CR1","first-page":"106","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta- analysis. Lancet. 2014;2:106\u201316.","journal-title":"Lancet"},{"key":"2407_CR2","unstructured":"Department of Health. PBS Expenditure and Prescriptions Report 1 July 2019 to 30 June 2020. (PBS Information Management Section, Canberra, ACT, 2020."},{"key":"2407_CR3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/08820538.2016.1181192","volume":"32","author":"I Chatziralli","year":"2017","unstructured":"Chatziralli I, Mitropoulos P, Parikakis E, Niakis D, Labiris G. Risk factors for poor quality of life among patients with age-related macular degeneration. Semin Ophthalmol. 2017;32:772\u201380.","journal-title":"Semin Ophthalmol"},{"key":"2407_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1590\/1516-3180.2018.0195071218","volume":"137","author":"S Inan","year":"2019","unstructured":"Inan S, Cetinkaya E, Duman R, Dogan I, Inan UU. Quality of life among patients with age-related severe macular degeneration assessed using the NEI-VFQ, HADS-A, HADS-D and SF-36 tests. A cross-sectional study. Sao Paulo Med J. 2019;137:25\u201332.","journal-title":"Sao Paulo Med J"},{"key":"2407_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2017.03.005","volume":"177","author":"H Senra","year":"2017","unstructured":"Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of Anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol. 2017;177:213\u201324.","journal-title":"Am J Ophthalmol"},{"key":"2407_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaophthalmol.2016.0794","volume":"134","author":"F Choudhury","year":"2016","unstructured":"Choudhury F, Varma R, Klein R, Gauderman J, Azen PA, McKean-Cowden R. Age-related macular degeneration and quality of life in Latinos: The Los Angeles Latino Eye Study. JAMA Ophthalmol. 2016;134:683\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"2407_CR7","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s11136-017-1547-z","volume":"26","author":"YM Paulus","year":"2017","unstructured":"Paulus YM, Jefferys JL, Hawkins BS, Scott AW. Visual function quality of life measure changes upon conversion to neo-vascular age-related macular degeneration in second eyes. Qual Life Res. 2017;26:2139\u201351.","journal-title":"Qual Life Res"},{"key":"2407_CR8","doi-asserted-by":"publisher","unstructured":"Elshout M, Webers CA, van der Reis M, de Jong-Hesse Y, Schouten JS Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study. BMC Ophthalmol (2017). https:\/\/doi.org\/10.1186\/s12886-017-0514-3.","DOI":"10.1186\/s12886-017-0514-3"},{"key":"2407_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000433448","volume":"234","author":"E Matamoros","year":"2015","unstructured":"Matamoros E, Maurel F, L\u00e9on N, Solomiac A, Bardoulat I, Joubert M, et al. Quality of life in patients suffering from active exudative age-related macular degeneration: the EQUADE study. Ophthalmologica. 2015;234:151\u20139.","journal-title":"Ophthalmologica"},{"key":"2407_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/archopht.116.4.514","volume":"116","author":"RA Williams","year":"1998","unstructured":"Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116:514\u201320.","journal-title":"Arch Ophthalmol"},{"key":"2407_CR11","doi-asserted-by":"publisher","unstructured":"Deteram HD, Liew G, Russell J, Vu KV, Burlutsky G, Mitchell P et al. Dietary antioxidants are associated with presence of intra- and sub-retinal fluid in neovascular age-related macular degeneration after 1 year. Acta Ophthalmol (2020). https:\/\/doi.org\/10.1111\/aos.14394.","DOI":"10.1111\/aos.14394"},{"key":"2407_CR12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"C Mangione","year":"2001","unstructured":"Mangione C, Lee P, Gutierrez PR, Spritzer K, Berry S, Hays RD, et al. Development of the 25-item national eye institute visual function questionnaire. Arch Ophthalmol. 2001;119:1050\u20138.","journal-title":"Arch Ophthalmol"},{"key":"2407_CR13","volume-title":"SF-36 Physical and mental health summary scales: a user\u2019s manual","author":"JE Ware","year":"1994","unstructured":"Ware JE. SF-36 Physical and mental health summary scales: a user\u2019s manual. Boston, MA: The Health Institute, New England Medical Centre; 1994."},{"key":"2407_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group.","year":"1990","unstructured":"The EuroQol Group. EuroQol \u2013 a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"2407_CR15","unstructured":"EuroQol. Choosing a value set. 2018. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-3l-about\/valuation\/choosing-a-value-set\/."},{"key":"2407_CR16","unstructured":"Duke University Centre for the Study of Aging and Human Development. OARS Multidimensional Functional Assessment Questionnaire. 1975."},{"key":"2407_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"L Radloff","year":"1977","unstructured":"Radloff L. The CESD-D scale: a self-report depression scale for research in general population. Appl Psychol Meas. 1977;1:385\u2013401.","journal-title":"Appl Psychol Meas"},{"key":"2407_CR18","volume-title":"Medical Statistics: A guide to SPSS, Data Analysis and Critical Appraisal","author":"B Barton","year":"2014","unstructured":"Barton B, Peaton J. Medical Statistics: A guide to SPSS, Data Analysis and Critical Appraisal. 2nd edn. Sydney: Blackwell Publishing; 2014.","edition":"2nd edn"},{"key":"2407_CR19","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.ophtha.2013.12.032","volume":"121","author":"RP Finger","year":"2014","unstructured":"Finger RP, Guymer RH, Gillies MC, Keefe JE. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology. 2014;121:1246\u201351.","journal-title":"Ophthalmology"},{"key":"2407_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00417-016-3477-9","volume":"255","author":"M Zhu","year":"2017","unstructured":"Zhu M, Wijeyakumar W, Syed AR, Joachim N, Hong T, Broadhead GK, et al. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration. Graefs Arch Clin Exp Ophthalmol. 2017;255:475\u201384.","journal-title":"Graefs Arch Clin Exp Ophthalmol"},{"key":"2407_CR21","doi-asserted-by":"publisher","unstructured":"Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration \u2013 a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol (2020). https:\/\/doi.org\/10.1186\/s12886-020-01554-2.","DOI":"10.1186\/s12886-020-01554-2"},{"key":"2407_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/hex.12046","volume":"18","author":"A Sav","year":"2015","unstructured":"Sav A, King MA, Whitty JA, Kendall E, McMillan SS, Kelly F, et al. Burden of treatment for chronic illness: a concept analysis and review of the literature. Health Expect. 2015;18:312\u201324.","journal-title":"Health Expect"},{"key":"2407_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaophthalmol.2013.2597","volume":"131","author":"X Zhang","year":"2013","unstructured":"Zhang X, Bullard KM, Cotch MF, Wilson MR, Rovner BW, MgGwin G Jr, et al. Association between depression and functional vision in loss in persons 20 years of age or older in the United States, NHANES 2005-2008. JAMA Ophthalmol. 2013;131:573\u201381.","journal-title":"JAMA Ophthalmol"},{"key":"2407_CR24","doi-asserted-by":"publisher","unstructured":"Vu KV, Mitchell P, Detaram HD, Burlutsky G, Liew G, Gopinath B Prevalence and risk factors for depressive symptoms in patients with neovascular age-related macular degeneration who present for anti-VEGF therapy. Acta Ophthalmol (2021). https:\/\/doi.org\/10.1111\/aos.14635.","DOI":"10.1111\/aos.14635"},{"key":"2407_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.maturitas.2013.12.001","volume":"77","author":"B Gopinath","year":"2014","unstructured":"Gopinath B, Liew G, Burlutsky G, Michell P. Age-related macular degeneration and 5-year incidence of impaired activities of daily living. Maturitas. 2014;77:263\u20136.","journal-title":"Maturitas"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02407-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02407-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02407-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T08:11:02Z","timestamp":1693987862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-023-02407-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2407"],"URL":"https:\/\/doi.org\/10.1038\/s41433-023-02407-0","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"28 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}